Cargando…
Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study
PURPOSE: MET is a notable driver gene in the diversity of aberrations with clinical relevance, including exon 14 skipping, copy number gain, point mutations, and gene fusions. Compared with the former two, MET fusions are severely under‐reported, leaving a series of unanswered questions. In this stu...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358190/ https://www.ncbi.nlm.nih.gov/pubmed/37326363 http://dx.doi.org/10.1002/cam4.6047 |
_version_ | 1785075610488406016 |
---|---|
author | Xia, Hui Zhang, Junhua Chen, Tong Wang, Mingzhao Chen, Dongna Si, Tongguo Liu, Yutao |
author_facet | Xia, Hui Zhang, Junhua Chen, Tong Wang, Mingzhao Chen, Dongna Si, Tongguo Liu, Yutao |
author_sort | Xia, Hui |
collection | PubMed |
description | PURPOSE: MET is a notable driver gene in the diversity of aberrations with clinical relevance, including exon 14 skipping, copy number gain, point mutations, and gene fusions. Compared with the former two, MET fusions are severely under‐reported, leaving a series of unanswered questions. In this study, we addressed this gap by characterizing MET fusions in a large, real‐world Chinese cancer population. METHODS: We retrospectively included patients with solid tumors who had DNA‐based genome profiles acquired through targeted sequencing from August 2015 to May 2021. MET fusion‐positive (MET+) patients were subsequently selected for clinical and molecular characterization. RESULTS: We screened 79,803 patients across 27 tumor types and detected 155 putative MET fusions from 122 patients, resulting in an overall prevalence of 0.15%. Lung cancer comprised the majority of MET+ patients (92, 75.4%). Prevalence was markedly higher in liver cancer, biliary tract cancer, and renal cancer (range 0.52%–0.60%). It was lower in ovarian cancer (0.06%). A substantial proportion (48/58, 82.8%) of unique partners were reported for the first time. High heterogeneity was observed for partners, with ST7, HLA‐DRB1, and KIF5B as the three most common partners. Mutational landscape analysis of lung adenocarcinoma (n = 32) revealed a high prevalence of TP53 in MET+ alterations, EGFR L858R, EGFR L861Q, and MET amplification. CONCLUSION: To our knowledge, this is currently the largest study in characterizing MET fusions. Our findings warrant that further clinical validation and mechanistic study may translate into therapeutic avenues for MET+ cancer patients. |
format | Online Article Text |
id | pubmed-10358190 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103581902023-07-21 Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study Xia, Hui Zhang, Junhua Chen, Tong Wang, Mingzhao Chen, Dongna Si, Tongguo Liu, Yutao Cancer Med RESEARCH ARTICLES PURPOSE: MET is a notable driver gene in the diversity of aberrations with clinical relevance, including exon 14 skipping, copy number gain, point mutations, and gene fusions. Compared with the former two, MET fusions are severely under‐reported, leaving a series of unanswered questions. In this study, we addressed this gap by characterizing MET fusions in a large, real‐world Chinese cancer population. METHODS: We retrospectively included patients with solid tumors who had DNA‐based genome profiles acquired through targeted sequencing from August 2015 to May 2021. MET fusion‐positive (MET+) patients were subsequently selected for clinical and molecular characterization. RESULTS: We screened 79,803 patients across 27 tumor types and detected 155 putative MET fusions from 122 patients, resulting in an overall prevalence of 0.15%. Lung cancer comprised the majority of MET+ patients (92, 75.4%). Prevalence was markedly higher in liver cancer, biliary tract cancer, and renal cancer (range 0.52%–0.60%). It was lower in ovarian cancer (0.06%). A substantial proportion (48/58, 82.8%) of unique partners were reported for the first time. High heterogeneity was observed for partners, with ST7, HLA‐DRB1, and KIF5B as the three most common partners. Mutational landscape analysis of lung adenocarcinoma (n = 32) revealed a high prevalence of TP53 in MET+ alterations, EGFR L858R, EGFR L861Q, and MET amplification. CONCLUSION: To our knowledge, this is currently the largest study in characterizing MET fusions. Our findings warrant that further clinical validation and mechanistic study may translate into therapeutic avenues for MET+ cancer patients. John Wiley and Sons Inc. 2023-06-16 /pmc/articles/PMC10358190/ /pubmed/37326363 http://dx.doi.org/10.1002/cam4.6047 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | RESEARCH ARTICLES Xia, Hui Zhang, Junhua Chen, Tong Wang, Mingzhao Chen, Dongna Si, Tongguo Liu, Yutao Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study |
title | Molecular characterization of
MET
fusions from a large real‐world Chinese population: A multicenter study |
title_full | Molecular characterization of
MET
fusions from a large real‐world Chinese population: A multicenter study |
title_fullStr | Molecular characterization of
MET
fusions from a large real‐world Chinese population: A multicenter study |
title_full_unstemmed | Molecular characterization of
MET
fusions from a large real‐world Chinese population: A multicenter study |
title_short | Molecular characterization of
MET
fusions from a large real‐world Chinese population: A multicenter study |
title_sort | molecular characterization of
met
fusions from a large real‐world chinese population: a multicenter study |
topic | RESEARCH ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358190/ https://www.ncbi.nlm.nih.gov/pubmed/37326363 http://dx.doi.org/10.1002/cam4.6047 |
work_keys_str_mv | AT xiahui molecularcharacterizationofmetfusionsfromalargerealworldchinesepopulationamulticenterstudy AT zhangjunhua molecularcharacterizationofmetfusionsfromalargerealworldchinesepopulationamulticenterstudy AT chentong molecularcharacterizationofmetfusionsfromalargerealworldchinesepopulationamulticenterstudy AT wangmingzhao molecularcharacterizationofmetfusionsfromalargerealworldchinesepopulationamulticenterstudy AT chendongna molecularcharacterizationofmetfusionsfromalargerealworldchinesepopulationamulticenterstudy AT sitongguo molecularcharacterizationofmetfusionsfromalargerealworldchinesepopulationamulticenterstudy AT liuyutao molecularcharacterizationofmetfusionsfromalargerealworldchinesepopulationamulticenterstudy |